Heterozygous familial hypercholesterolemia case study

Journal of the American Academy of Nurse Practitioners

Volumn 22, Issue 10, 2010, Pages 523-526

  Friedrich, Debra A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiovascular disease; Cardiovascular risk; Case study; Hypercholesterolemia

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; SULFONAMIDE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; LIFESTYLE; MALE; PATHOLOGY; RISK ASSESSMENT; UNITED STATES;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; MALE; PYRIMIDINES; RISK ASSESSMENT; SIMVASTATIN; SULFONAMIDES; UNITED STATES;

EID: 78650480026     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2010.00545.x     Document Type: Article

References (16)

1. Austin, M. A., Hutter, C. M., Zimmerman, R. L., & Hymphries, S. E. (2004). Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence preview. American Journal of Epidemiology, 160, 408-420.
2. Ballantyne, C. (2009). Clinical lipidology: A companion to Braunwald's heart disease. Philidelphia, PA Saunders Elsevier.
3. Berg, K., & Heiberg A. (1978). Linkage between familial hypercholesterolemia with xanthomatosis and the C3 polymorphism confirmed. Cytogenet Cell Genet, 22, 621-623.
4. Brown, M. S., & Goldstein J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science, 232, 34-47.
5. Centers for Disease Control and Prevention. (2008). About heart disease. Retrieved January 12, 2009, from
6. Citkowitz, E. (2008). Familial hypercholesterolemia. Retrieved January 21, 2009, from
7. Davidson, M. H., Toth, P. P., & Maki, K. C. (2007). Therapeutic lipidology. Totowa, NJ Human Press, Inc.
8. Elston, R. C., & Namboodiri, K. K. (1976). Probably linkage between essential familial hypercholesterolemia and third complement component. Cytogenetics and Cell Genetics, 16, 294-297.
9. Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967). Fat transport in lipoproteins: An integrated approach to mechanisms and disorders. New England Journal of Medicine, 276, 215-225.
10. Hitti, M. (2008). FDA OKs new cholesterol drug trilipix. WebMD. Retrieved July 13, 2009, from
11. Marais, A. D. (2004). Familial hypercholesterolaemia. Clinical Biochemistry Review, 25, 49-68.
12. Ott, J., Schrott, H. G., & Goldstein, J. L. (1974). Linkage studies in a large kindred with familial hypercholesterolemia. American Journal of Human Genet, 26, 598-603.
13. Sibley, C. (2006). Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleveland Clinic Journal of Medicine, 73, 57-64.
14. Tosi, I., Toledo-Leiva, P., Neurwirth, C., Naoumova, R. P., & Soutar, A. K. (2007). Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis, 194, 102-111.
15. Watts, G. F., Hamilton-Craig, I., & Sullivan, D. R. (2008). NICE guidance on familial hypercholesterolaemia: All sugar and spice? Heart Lung Circulation, 18, 181-183.
16. Yuan, G., Wang, J., & Hegele, R.A. (2006). Heterozygous familial hypercholesterol: An underrecognized cause of early cardiovascular disease. Canadian Medical Association Journal, 174, 1124-1129.